<DOC>
	<DOCNO>NCT01266057</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose sirolimus vorinostat give combination hydroxychloroquine patient advance cancer . The safety drug combination also study .</brief_summary>
	<brief_title>Sirolimus Vorinostat Hydroxychloroquine Advanced Cancer</brief_title>
	<detailed_description>Study Drug Dose Level : If find eligible take part study , assign dose level hydroxychloroquine either sirolimus vorinostat , base join study , availability spot drug combination , doctor think best interest . Up 11 dose level sirolimus hydroxychloroquine combination 7 dose level vorinostat hydroxychloroquine combination test . Three ( 3 ) 6 participant enrol dose level . The first group participant receive low dose level study drug combination . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose drug combination find . Once high tolerate dose drug combination find , 28 participant ( 14 per combination ) give dose . The study doctor decide drug combination participant give , base tumor type . Study Drug Administration : Each study `` cycle '' 21 day . You take hydroxychloroquine either vorinostat sirolimus mouth , 1 time day , every day . You take pill time day food cup ( 8 ounce ) water . Study Visits : At every study visit , ask health condition , drug may take , side effect . Weekly During Cycle 1 : Â° Blood ( 2 teaspoon ) draw routine test . At begin cycle begin 2 : - You physical exam . - Your medical history record . - You ask muscle weakness difficulty move . Every 6 week , x-ray , CT scan , MRI scan , and/or PET/CT check status disease . If study doctor think need , perform often . If able become pregnant , blood ( 1 teaspoon ) urine pregnancy test . About every 3 month , eye exam . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . This investigational study . Sirolimus FDA approve commercially available treatment patient kidney transplant . Vorinostat FDA approve commercially available treatment cutaneous T-cell lymphoma . Hydroxychloroquine FDA approve commercially available treat malaria . The use drug combination investigational . Up 224 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy available improves survival least three month . 2 . Patients must &gt; /= 18 year . 3 . Patients must &gt; /= 3 week beyond treatment cytotoxic chemotherapy regimen , therapeutic radiation , major surgery . Patients may receive palliative localize radiation immediately treatment provide radiation deliver site disease treat protocol . For biologic/targeted agent patient must &gt; /= 5 halflives &gt; /= 3 week form last dose ( whichever come first ) . 4 . ECOG performance status &lt; /= 2 5 . Patients must adequate organ marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; /= 2 X ULN ; total bilirubin &lt; /= 2.0 ( exception may apply benign nonmalignant indirect hyperbilirubinemia Gilbert syndrome ) ; ALT ( SGPT ) &lt; /= 5 X ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; ALT ( SGPT ) &lt; /= 8 X ULN ; cholesterol &lt; /= 350 mg/dL ; triglyceride &lt; /= 400 mg/dL ( sirolimus hydroxychloroquine ) . 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 7 . Patients must able understand willing sign write informed consent document . 1 . Uncontrolled intercurrent illness , include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . 2 . Pregnant lactating woman . 3 . History hypersensitivity sirolimus . 4 . History hypersensitivity vorinostat 5 . History hypersensitivity hydroxychloroquine 6 . History hypersensitivity component formulation . 7 . Patients unwilling unable sign inform consent document . 8 . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . 9 . Patients know glucose6phosphate dehydrogenase deficiency . 10 . Patients porphyria cutanea tarda . 11 . Patients psoriasis . 12 . Patients preexist maculopathy retinopathy eye . 13 . Patients preexist myopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Plaquenil</keyword>
	<keyword>Rapamune</keyword>
	<keyword>Saha</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
</DOC>